柬埔寨村庄控制性试验:群体服药阻断多重耐药恶性疟原虫传播
在柬埔寨西部4个疟疾流行村开展随机对照试验,比较早期与期末3轮群体服药(双氢青蒿素-磷酸哌喹3天疗程)效果。服药覆盖率至少1轮88%、≥2轮73%、3轮58%。干预村服药后12个月恶性疟发病率1.5/1000人年 vs 对照村37.1/1000人年(发病率比24.5,95%CI 3.4-177,P=.002)。2016年服药后4村12个月内无临床恶性疟病例(0/2044人年)。
要点
- 群体服药至少1轮覆盖88%(1999/2268),3轮覆盖58%(1310/2268)。
- 服药后12个月干预村恶性疟发病率1.5/1000人年 vs 对照村37.1/1000人年,发病率比24.5(95%CI 3.4-177,P=.002)。
- 2016年服药后4村12个月内无临床恶性疟病例(0/2044人年),未见归因于治疗的严重不良事件。
核心结论
- 群体服药覆盖率高、安全,并与至少1年无临床恶性疟病例相关。
研究设计与样本
- 柬埔寨西部4个疟疾流行村随机分组,分别在研究早期或期末接受3轮群体服药(双氢青蒿素-磷酸哌喹3天疗程)。
- 收集2014-2017年疟疾治疗记录,每季度以超敏定量聚合酶链反应估计亚临床寄生虫患病率,共12个月。
主要发现
- 服药至少1轮覆盖率88%(1999/2268),≥2轮73%(1645/2268),3轮58%(1310/2268)。
- 研究前12个月干预村与对照村恶性疟发病率相似:39/1000人年 vs 45/1000人年(P=.50)。
- 服药后12个月主要结局恶性疟发病率干预村低于对照村:1.5/1000人年 vs 37.1/1000人年,发病率比24.5(95%CI 3.4-177,P=.002)。
- 2016年服药后4村12个月内无临床恶性疟病例(0/2044人年)。
- 间日疟患病率在干预村服药后明显下降,但12个月时回升至基线患病率约一半。
关键数值与推荐
- 群体服药方案为双氢青蒿素-磷酸哌喹3天疗程,共3轮。
- 主要结局为服药后12个月恶性疟发病率,干预村1.5/1000人年 vs 对照村37.1/1000人年,发病率比24.5(95%CI 3.4-177,P=.002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The increase in multidrug-resistant Plasmodium falciparum in Southeast Asia suggests a need for acceleration of malaria elimination. We evaluated the effectiveness and safety of mass drug administration (MDA) to interrupt malaria transmission. METHODS: Four malaria-endemic villages in western Cambodia were randomized to 3 rounds of MDA (a 3-day course of dihydroartemisinin with piperaquine-phosphate), administered either early in or at the end of the study period. Comprehensive malaria treatment records were collected during 2014-2017. Subclinical parasite prevalence was estimated by ultrasensitive quantitative polymerase chain reaction quarterly over 12 months. RESULTS: MDA coverage with at least 1 complete round was 88% (1999/2268), ≥2 rounds 73% (1645/2268), and all 3 rounds 58% (1310/2268). Plasmodium falciparum incidence in intervention and control villages was similar over the 12 months prior to the study: 39 per 1000 person-years (PY) vs 45 per 1000 PY (P = .50). The primary outcome, P. falciparum incidence in the 12 months after MDA, was lower in intervention villages (1.5/1000 PY vs 37.1/1000 PY; incidence rate ratio, 24.5 [95% confidence interval], 3.4-177; P = .002). Following MDA in 2016, there were no clinical falciparum malaria cases over 12 months (0/2044 PY) in all 4 villages. Plasmodium vivax prevalence decreased markedly in intervention villages following MDA but returned to approximately half the baseline prevalence by 12 months. No severe adverse events were attributed to treatment. CONCLUSIONS: Mass drug administrations achieved high coverage, were safe, and associated with the absence of clinical P. falciparum cases for at least 1 year. CLINICAL TRIALS REGISTRATION: NCT01872702.
引用
- Tripura R, Peto TJ, Chea N, et al. A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages. Clin Infect Dis. 2018. PMID: 29522113. doi:10.1093/cid/ciy196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。